Unfortunately, the positive effect of anakinra on post-stroke mortality and disability was not confirmed by the subsequent, larger, Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke (SCIL-STROKE) trial [213], although the significant reduction of IL-6 and CRP circulating levels after 3 days was confirmed. This evidence concerns the gene IL6 and Stroke.